← All trials
NCT04356638
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2020
- Primary completion
- Apr 1, 2021
- Completion date
- Dec 31, 2021
- First posted
- Apr 22, 2020
- Last posted
- Apr 22, 2020
- Enrollment
- 80
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- King Faisal UniversityLead sponsor
- King Faisal UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.